Clinical trial · Interventional
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer
NCT03170180CI-TRIAL-00059139completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
1. Metastatic gastric cancer patients who failed standard treatment will be enrolled in this study. 2. After consent form, patient-derived cancer cell will be collected and tested with 3 kinds of drugs (sunitinib, gefitinib, imatinib). 3. Drug sensitivity prediction software (IRCR-DReSS) will present level of sensitivity and patients will be treated with sensitive drugs. 4. Patients will be evaluated every 6 weeks.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stomach Neoplasms | Gastric Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (3)
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- sunitinib
- interventionNames
- Drug: Sunitinib
- type
- EXPERIMENTAL
- label
- gefitinib
- interventionNames
- Drug: Gefitinib
- type
- EXPERIMENTAL
- label
- imatinib
- interventionNames
- Drug: Imatinib
Primary outcomes (1)
- measure
- response rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * age\>-20 * metastatic gastric cancer * life expectancy \>-3 months * ascites and pleural effusion that can be drained * ECOG 0-2 * Proper organ function * Patients who will be enrolled in sunitinib, gefitinib, imatinib clinical trial Exclusion Criteria: * HBeAg, HCV, HIV (+) * Active infection * Uncontrolled systemic disease
References
Publications (0)
Data not yet available
No reference posted for this study.